Novartis signs agreement to acquire Anthos Therapeutics for $925 million upfront
LONDON: Novartis has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, clinical-stage biopharmaceutical company. Under the agreement, Novartis will pay USD 925...
Novartis will acquire Mariana Oncology for up to $1.75 billion
Novartis will acquire Mariana Oncology, a fully integrated biotechnology company and pioneer in a new era of radiopharmaceutical innovation for treating people with cancer, for...
Novartis to spin off Sandoz in October 2023
Novartis, the Swiss drugmaker, has announced that it will spin off its generic medicines division, Sandoz, on or around Oct. 4, subject to shareholder approval....
Novartis to acquire Chinook Therapeutics for $3.5 billion
Novartis, the Swiss pharmaceutical giant, has announced its agreement to acquire Chinook Therapeutics, a biotech firm based in Seattle, in a deal valued at up...
Novartis to buy Syncona’s Gyroscope Therapeutics for $1.5bn
LONDON, UK: Syncona Ltd has been reached to sell its portfolio company Gyroscope Therapeutics Holdings to Novartis for up to $1.5 billion on a cash...
Artios collaborates with Novartis to create next generation DDR cancer therapies
LONDON: Arix Bioscience’s portfolio company Artios Pharma Limited announced a global research collaboration with Novartis to discover and validate next generation DDR targets to enhance...
Takeda assesses financial impact from Novartis’ withdrawal of marketing authorisation application for Xiidra
OSAKA: Takeda Pharmaceutical Company Limited announced the anticipated financial impact from Novartis Europharm Limited’s withdrawal of the Marketing Authorisation Application (MAA) for Xiidra in Europe,...